Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks six (6) psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances (read 10 Psychedelic Substances And The 36 Companies Researching Them), and have market capitalizations in excess of $50M.

Below are the performances of the 6 constituents this past week, in descending order:

1. Seelos (SEEL): UP 2.8% 
   • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.
2. Mind Medicine (MNMD): DOWN 0.4% 
   • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
3. Cybin (CYBN): DOWN 8.3% 
   • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
4. Compass Pathways (CMPS): DOWN 8.6%
   • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
5. Atai (ATAI): DOWN 9.9% 
   • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
6. GH Research (GHRS): DOWN 11.8% 
   • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.

In total, the Index went DOWN 8.9% last week and is now DOWN 51.0% YTD.

Six (6) other psychedelic companies are primarily focused on the development, expansion, and operation of ketamine-assisted therapy (KAT) clinics hoping to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction, and substance abuse withdrawal, and depression. All are highly speculative investments and penny stocks with tiny market capitalization and are identified below with a description of each of their commercialization developments and their stock performances last week in ascending order:

1. Delic Corp. (CSE: DELC|OTCQB: DELCF); DOWN 33.3%
   • Has 13 ketamine-assisted therapy (KAT) clinics in the U.S.
2. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF); DOWN 33.3%
   • Has 10 KAT clinics in 6 states and 9 options on other clinics
3. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF); DOWN 25.8%
   • Is concentrating on the treatment of Alcohol Use Disorder (AUM)
     • has 3 KAT clinics, 2 in the U.K. and 1 in Norway and
     • is developing MDMA-assisted therapy for AUM
   •  Is also in the process of developing KAT for Gambling Disorder
   • Go here for the company's latest quarterly (Q2) financial results
4. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF); DOWN 11.1%
   • Is concentrating on therapies for the treatment of resistant depression, post-traumatic stress disorder and disorders affecting the central nervous systems
   • Operates KAT clinics in Canada (3), the U.S. (8) and Europe (1)
5. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF); DOWN 11.1%
   • has 3 KAT clinics in Canada,
   • has the ability to undertake treatments using psilocybin and MDMA in Canada as authorized by Health Canada's Special Access Program and
   • has 6 KAT clinics in Utah and 2 in Arizona
6. Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF); No Change
   • Is concentrating on the treatment of Opioid Use Disorder using ibogaine which has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the U.S.) facilitating research and development toward medicalization.

The above psychedelic-assisted therapy clinic stocks went DOWN 19.7%, on average, last week and are now DOWN 50.9% since the end of August.

More By This Author:

Largest American Cannabis Stocks Collapsed 35% This Week
The 5 Largest Canadian Cannabis Stocks Dropped 24.5% This Week
Metaverse Stocks Index Went Up 4% In November; Still Down 47% YTD